Tulane Medicine team prepares for BIO2023

Bio 2022 picture

The annual Biotechnology Innovation Organization conference, better known as BIO, attracts thousands of biotechnology and pharmacology leaders from around the globe. Researchers and business leaders from Tulane University School of Medicine will be among the 14,000+ in attendance at BIO2023 to spread the word about the research and innovation happening here.

BIO gives the Tulane Medicine team the opportunity to connect with existing collaborators and establish new relationships. Along with some of the outstanding scientists at the School of Medicine, the Tulane team will include James Zanewicz, JD, LLM, RTTP, Chief Business Officer; Elaine Hamm, PhD, Executive in Residence; and Kay Genemaras, PhD, Business Development Associate.

"If you would like to schedule a 1-1 session at BIO2023 and learn how we can help you advance your mission, please reach out and ask for a meeting,” said Zanewicz. “We understand how crucial the relationship between academic medical centers and the world around us is to advance the fields of biotech and healthcare, and we’re passionate about finding new ways to continue doing so. BIO inspires us to think outside the realm of what has always been done and think about what could be possible."

The Tulane Medicine team's participation in BIO 2023 is a testament to their commitment to building strong relationships with partners and promoting innovation and growth in the biotech and healthcare industries. With their unique approach to business development and corporate engagement, the team is poised to make a significant impact on the industry and drive positive change for years to come.

Companies, Investors, Family Offices and other collaborators are encouraged to take note, as Tulane Medicine’s model for business development and industry engagement has proven to be highly successful. Their impressive ROI has included assisting in moving millions of dollars of contracts forward, attracting clinical trials from major entities such as Bayer, and making license connections for numerous innovations arising from the minds of Tulane’s researchers.

But their success goes beyond such traditional metrics as well, and Zanewicz attributes this success to a different philosophy that recognizes the importance of maintaining strong relationships with partners, even if it's not immediately beneficial to Tulane Medicine.

“This often involves preventing issues before they occur, building trust, and providing resources to assist partners in their own endeavors,” Zanewicz said. "Our approach is truly about building relationships, and we take a long-term view on everything we do.”

"We want to understand our partners' needs, and then provide support that helps them achieve their goals. Sometimes that means delivering measurable ROI, but often it's about building trust and maintaining a strong relationship over time."

The Office of Research Business Development also support Tulane’s cohort of emerging biotech companies.  A key example is BioAesthetics, a startup that develops tissue-engineered solutions for breast reconstruction.  The Tulane Medicine team enabled BioAesthetics to get into the IndieBio program in San Francisco, which provided critical support for the company's growth.

But they also have less traditional wins, including producing the podcast BIO from the BAYOU, and the Tulane Digest, which shares information about scientific advances with the world. Tulane Medicine’s Office of Research Business Development also hosts the regional BIO on the BAYOU event showcasing science from over a dozen universities in the Gulf South, which returns this October after a successful 2022 event.